Close menu




September 21st, 2020 | 07:22 CEST

Grenke, JinkoSolar, Velocity Minerals - continue buying gold or are there alternatives?

  • Investments
Photo credits: pixabay.com

Nowhere in the world, was more gold bought in the first six months of 2020 than in Germany. Coins and bars in the amount of about 83 tons went into the hands of the citizens. According to the World Gold Council, this represents an increase of 120% compared to the same period last year and equates to roughly EUR 4.4 billion in value. Those investors who do not want to be involved in the storage of gold, but still want a well-diversified portfolio with precious metal content, should look at shares in the value chain.

time to read: 2 minutes | Author: Mario Hose
ISIN: CA92258F3007 , US47759T1007 , DE000A161N30

Table of contents:


    Gold in Europe

    Canadian exploration company Velocity Minerals is focused on the discovery and development of gold deposits in Bulgaria. The fact that the company operates within the structure and stability of the European Union should be considered a clear advantage. In August of this year, the Company released the results of a pre-feasibility study for the Rozino project, which confirmed open-pit mining as a viable option for future gold production. Last week, the Company was able to announce drill results from their Kazak Project which were encouraging. Kazak is located approximately two kilometres from Rozino. The development in the vicinity is important as it can positively influence and expand Rozino's planning.

    "The discovery of gold mineralization at Kazak is important to the Rozino project because additional gold discoveries at proximity to a future processing plant at Rozino have the potential to add significant value to the project with relatively little investment," stated Keith Henderson, CEO of Velocity. "Velocity's exploration program has identified several exploration targets between Kazak and Rozino within a target corridor of five kilometres long by two kilometres wide. With an extensive exploration program in this area and other gold projects in the region, we aim to delineate additional gold resources that may fit into Velocity's hub and bespoke development model.

    Q2 results eagerly awaited

    The Chinese company JinkoSolar was founded in 2006 and is focused on the production and sale of solar cells, modules and mounting systems. On the stock exchange, JinkoSolar was able to surprise the capital market with a large order of 611MW from Vietnam, resulting in a move in the share price. The market capitalization was around USD 1.0 billion on Friday at a closing price of USD 24.50. Whether this rise in the share price will be sustainable will certainly be decided following the publication of the second-quarter results on September 23, 2020.

    The stakes are high

    The scandal surrounding the Wirecard bankruptcy has not yet been dealt with, and speculation about a possible new scandal is already breaking in on investors. This time it concerns the MDAX company, Grenke. The accusations made by the short-sellers cover several different criminal offences. While investors should be confident with the work of the auditors, the authorities and the Supervisory Board as a controlling body, the Wirecard scandal has proven to market players that all controlling bodies can fail.

    Whether Grenke is now the victim of a defamation campaign or has been unmasked is not yet certain. What is obvious, however, is that trust in companies and their auditors have already dwindled as a result of initial suspicions. Meanwhile, investors are increasingly and probably justifiably asking themselves why short-sellers see more and understand critical relationships better than auditors and regulatory authorities. Grenke's share price opened the previous week at EUR 55.00 and fell to a low of less than EUR 24.00. A statement of the company ensured that the share could go into the weekend at around EUR 34.00. The confidence in the financial centre of Frankfurt is now at stake.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read